Calamos Advisors LLC Has $1.50 Million Stock Holdings in Revolution Medicines, Inc. $RVMD

Calamos Advisors LLC grew its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD) by 24.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,463 shares of the company’s stock after acquiring an additional 3,003 shares during the quarter. Calamos Advisors LLC’s holdings in Revolution Medicines were worth $1,504,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in the stock. Nextech Invest Ltd. boosted its holdings in Revolution Medicines by 20.7% during the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after purchasing an additional 1,304,347 shares in the last quarter. Millennium Management LLC increased its stake in shares of Revolution Medicines by 681.8% in the first quarter. Millennium Management LLC now owns 156,353 shares of the company’s stock valued at $5,529,000 after buying an additional 136,353 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Revolution Medicines by 14.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company’s stock valued at $10,615,000 after acquiring an additional 37,345 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Revolution Medicines by 19.3% in the second quarter. Invesco Ltd. now owns 227,019 shares of the company’s stock valued at $8,352,000 after purchasing an additional 36,760 shares in the last quarter. Finally, Jump Financial LLC raised its position in shares of Revolution Medicines by 87.9% during the second quarter. Jump Financial LLC now owns 15,258 shares of the company’s stock worth $561,000 after acquiring an additional 7,137 shares during the last quarter. Institutional investors own 94.34% of the company’s stock.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, Director Sushil Patel sold 5,580 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $187.99, for a total transaction of $1,048,984.20. Following the transaction, the director owned 21,656 shares in the company, valued at $4,071,111.44. This trade represents a 20.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jack Anders sold 20,000 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total value of $3,366,600.00. Following the completion of the transaction, the chief financial officer owned 123,269 shares in the company, valued at $20,749,870.77. The trade was a 13.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 132,497 shares of company stock valued at $21,470,486 over the last ninety days. 7.60% of the stock is owned by corporate insiders.

Revolution Medicines Stock Performance

Shares of RVMD stock opened at $179.18 on Friday. Revolution Medicines, Inc. has a 52 week low of $34.00 and a 52 week high of $193.82. The company has a market capitalization of $38.09 billion, a price-to-earnings ratio of -25.34 and a beta of 1.37. The company has a 50-day simple moving average of $164.18 and a 200 day simple moving average of $127.64. The company has a debt-to-equity ratio of 0.19, a quick ratio of 6.80 and a current ratio of 6.80.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) earnings per share for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same period in the previous year, the company posted ($1.13) earnings per share. On average, sell-side analysts predict that Revolution Medicines, Inc. will post -7.92 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on RVMD shares. Sanford C. Bernstein began coverage on shares of Revolution Medicines in a research report on Thursday, May 21st. They set a “market perform” rating and a $151.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $195.00 price objective on shares of Revolution Medicines in a research report on Monday, July 6th. Mizuho raised their target price on shares of Revolution Medicines from $185.00 to $215.00 and gave the stock an “outperform” rating in a report on Monday, July 6th. Stifel Nicolaus reissued a “buy” rating on shares of Revolution Medicines in a research note on Monday, April 20th. Finally, Evercore reissued an “outperform” rating on shares of Revolution Medicines in a research report on Tuesday, April 14th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Revolution Medicines presently has an average rating of “Moderate Buy” and a consensus price target of $144.00.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.